Engineered Immune Cells Protect Transplanted Insulin Cells in Type 1 Diabetes Research

A Fresh Approach to Type 1 Diabetes: Engineering Immunity for a Potential Cure

For decades, the pursuit of a cure for type 1 diabetes has centered on replacing the insulin-producing beta cells destroyed by the body’s own immune system. While transplantation offers a potential solution, the immune system often rejects these new cells, restarting the cycle of insulin dependence. Now, researchers are exploring a novel strategy: engineering immune cells to actively protect transplanted insulin-producing cells, offering a potential path toward lasting remission. This approach aims to circumvent the need for broad immunosuppression, which carries significant side effects, and could transform treatment for the approximately 2.1 million Americans living with type 1 diabetes, according to 2026 data from the Centers for Disease Control and Prevention (CDC).

The Challenge of Beta Cell Replacement

Type 1 diabetes is an autoimmune disease where the immune system mistakenly attacks and destroys beta cells in the pancreas. These cells are crucial for producing insulin, the hormone that regulates blood sugar levels. Without insulin, individuals must carefully monitor their glucose and administer insulin injections or use a pump to survive. While donor-based transplants can provide insulin independence, they require cells from multiple donors – often two to four – for a single recipient, and still face the challenge of immune rejection.

Researchers have increasingly turned to stem cells as a renewable source of insulin-producing cells. These cells can be grown in the lab and differentiated into functional beta cells, offering a potentially scalable solution. Although, even these lab-grown cells are vulnerable to immune attack once transplanted. The Medical University of South Carolina (MUSC) is at the forefront of addressing this challenge.

Guiding Protection to the Transplant Site

Dr. Leonardo Ferreira and his team at MUSC are pioneering a strategy that focuses on directing immune protection specifically to the site of the transplant, rather than suppressing the entire immune system. This targeted approach leverages the power of regulatory T cells (Tregs), a type of immune cell known for its ability to dampen immune responses. Tregs naturally assist prevent excessive immune attacks, but they circulate throughout the body, making it difficult to concentrate their protective effects where they are needed most.

To overcome this limitation, the researchers genetically modified the transplanted insulin-producing cells, adding a harmless molecular tag to their surface. This tag acts as a beacon, attracting engineered Tregs to the transplant site. The engineered Tregs are programmed to recognize this tag and congregate around the new cells, providing localized immune protection. This approach, as described in research supported by Breakthrough T1D (Breakthrough T1D), aims to create a microenvironment of immune tolerance around the transplanted cells.

Reprogramming Immune “Bodyguards”

The process involves not only modifying the insulin-producing cells but also reprogramming the protective immune cells themselves. Researchers are essentially turning Tregs into specialized “bodyguards” that actively seek out and defend the transplanted cells. Once they arrive at the transplant site, these modified Tregs release chemical signals that calm other immune cells, reducing the risk of attack. This targeted approach minimizes the impact on the overall immune system, potentially avoiding the broad-spectrum side effects associated with traditional immunosuppressive drugs.

Early Results and Future Directions

In preclinical studies using humanized mice – mice engineered to carry parts of the human immune system – the protective effect of this strategy has lasted for approximately four weeks. During this time, the transplanted insulin-producing cells remained intact even when researchers deliberately triggered an immune attack. While these results are promising, further research is needed to determine whether the protection can be sustained for longer periods and whether the approach remains safe over time.

The MUSC team is now focused on improving delivery methods and exploring the possibility of administering repeat doses of protective cells to maintain long-term protection. They are also investigating whether this strategy can be effective in individuals who have had type 1 diabetes for many years and have little to no remaining beta cell function. The ultimate goal is to develop a therapy that can work for all people with type 1 diabetes, regardless of the stage of their disease.

Avoiding the Risks of Broad Immunosuppression

Traditional transplant protocols often rely on immunosuppressive drugs to prevent rejection. However, these drugs arrive with a range of side effects, including increased susceptibility to infections and an elevated risk of certain cancers. By targeting immune protection specifically to the transplant site, this new strategy aims to avoid these risks. The potential to eliminate or significantly reduce the need for immunosuppressive drugs is a major driving force behind the research, and a key reason Breakthrough T1D has invested $1 million in the project. As Dr. Ferreira noted, the organization believes this represents the “next wave in type 1 diabetes therapy.”

The Immunology of Type 1 Diabetes: A Complex Landscape

Understanding the underlying immunology of type 1 diabetes is crucial for developing effective therapies. As outlined in a recent review published in Nature (Nature), the disease is characterized by a complex interplay of genetic predisposition and environmental triggers. Risk genes often impact T cell development and function, and the gut microbiome appears to play a significant role in disease pathogenesis. The autoimmune attack is primarily driven by T cells that target and destroy insulin-producing beta cells in the pancreas, a process known as insulitis. Recent advances in immunotherapy, such as the approval of teplizumab, a CD3-targeting monoclonal antibody, highlight the growing recognition of the immune system’s central role in the disease.

What’s Next: Clinical Trials and Long-Term Durability

The next critical step is to translate these promising preclinical results into clinical trials. Researchers will need to carefully assess the safety and efficacy of this approach in humans, starting with small-scale studies to determine the optimal dose and delivery method. A key focus will be on evaluating the long-term durability of the protective effect and ensuring that the engineered Tregs do not trigger unintended immune responses. Success will depend on demonstrating that the therapy can maintain insulin control without the need for chronic immunosuppression, offering a true path toward a cure for type 1 diabetes.